Discontinued — last reported Q4 '25
Products & Services · Upfront and milestone paymentsmade to collaborative partner
License — Upfront and milestone paymentsmade to collaborative partner
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityVolatile
First reportedQ4 2025
Last reportedQ4 2025
How to read this metric
An increase suggests higher investment in external innovation or successful progress in partnered clinical programs, while a decrease may indicate fewer new collaborations or a shift toward internal R&D.
Detailed definition
This metric represents the aggregate cash outflows paid to external collaborative partners for licensing intellectual pr...
Peer comparison
Comparable to 'Upfront and milestone payments' or 'In-process R&D expenses' found in the R&D or licensing sections of other biopharmaceutical companies.
Metric ID:
biib_segment_license_upfront_and_milestone_paymentsmade_to_collaborative_partnerHistorical Data
1 periods
| Q4 '25 | |
|---|---|
| Value | $50.00M |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Biogen's license — upfront and milestone paymentsmade to collaborative partner?
- Biogen (BIIB) reported license — upfront and milestone paymentsmade to collaborative partner of $50.00M in Q4 2025.
- What does license — upfront and milestone paymentsmade to collaborative partner mean?
- The total amount paid to partners for licensing rights and achieving development goals.